AbbVie Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AbbVie Inc. on October 16, 2018, regarding events occurring on October 19, 2018. The filing addresses Item 5.02, concerning the departure of certain officers and the appointment of new officers within the finance organization.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is a restructuring of the company's senior finance leadership:
- William J. Chase: The Executive Vice President and Chief Financial Officer announced plans to retire in mid-2019. Effective October 19, 2018, he was appointed Executive Vice President, Finance and Administration.
- Robert A. Michael: Appointed Senior Vice President and Chief Financial Officer, effective October 19, 2018. He will report to Mr. Chase in his new role. Mr. Michael has been with the company since 1993 (via Abbott Laboratories) and served as Vice President, Controller since March 2017.
- Brian L. Durkin: Appointed Vice President, Controller, effective October 19, 2018. He previously served as Vice President, Internal Audit since 2016.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on performance, risks, contingencies, or unusual items. The document is limited to the announcement of executive appointments and retirement plans.
Key Facts for Investor Verification
- Confirmation of the transition timeline for the Chief Financial Officer role between Robert A. Michael and William J. Chase.
- Verification of William J. Chase's retirement date in mid-2019.
- Review of subsequent filings to ensure no undisclosed financial impacts related to these leadership changes.